Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819780 · ClinicalTrials.gov registry record · Phase 2
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT00819780 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 285 participants.
The verdict
NCT00819780, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.
Interventions
- DRUG Bevacizumab
- DRUG Panitumumab
- DRUG mFOLFOX6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2009-04-24 |
| Est. Completion | 2016-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819780
The ClinicalTrials.gov registry entry for NCT00819780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00819780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00819780 about?
NCT00819780 is a clinical study titled "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors". The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.
What is the current status of trial NCT00819780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2009-04-24. Estimated completion is 2016-07-07.
What interventions are being tested in trial NCT00819780?
The interventions under investigation include: Bevacizumab (DRUG), Panitumumab (DRUG), mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT00819780?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.